SCMP : From Hermès to Rolls-Royce, luxury brands are selling escapism to lead us

From Hermès to Rolls-Royce, luxury brands are selling escapism to lead us – and the global economy – out of the Covid-19 pandemic
High-end retail typically rebounds dramatically faster in times of crisis, and as the world opens up and embraces a new normal, from demand for private planes to island escapes, luxury leaders have a key role to play in kick-starting the global economy

It may sound counter-intuitive, but I am certain the luxury sector will lead the rebound of the global economy once the coronavirus pandemic is over. At first glance this does not seem to make sense because the luxury sector is a relatively small part of the global economy. And often, when a crisis hits, many commentators are quick to write off the luxury industry and predict the emergence of austerity and “stealth consumption”.
If the past is an indicator for the future, this will not happen. Bain & Company showed in the 2019 “Luxury Goods Worldwide Market Study” that the global luxury market grew between 1996 and 2019 with a compound annual growth rate of 6 per cent, two times the growth of global GDP. This time frame included the dotcom bubble burst, the 9/11 attacks, Sars and the subprime and financial crisis of 2008/2009. In the entire period there was only one significant drop with an 8 per cent year-on-year decline in 2009, but 2010 was already exceeding 2008, significantly accelerating the growth of the luxury sector henceforth.
When we look at economic indicators after crises, high-end retail typically rebounds dramatically faster to pre-crisis level than low-end retails. And maybe the most alarming factor is the unemployment rate, which is typically one of the slowest to fully rebound. After the 2008 crisis, the unemployment rate in the US had only recovered to around 20 per cent of the pre-crisis rate by 2011. This indicates that a crisis hits customers and brands that are the most vulnerable hardest.

The Covid-19 pandemic compounds challenges that many luxury brands are already facing. But it also offers opportunities for those brands that excel in inspiring customers, creating value for them, evoking dreams and initiating memories. In fact, in times of crisis, luxury brands should connect stronger than ever before with their customers.

Luxury brands also need to tap into what I call the hidden drivers of luxury. Personal protection is such a hidden driver. It is the number one reason why the demand for private aviation is skyrocketing, and why those who can afford it try to organise their holidays at secluded places, far away from the crowds, such as private islands.
The director of one of the most exclusive luxury hotels in India told me recently that wealthy guests now often book the entire hotel, just to make sure they have total privacy. Gregory Day, the CEO of the Malibu Beach Inn, one of the most luxurious and intimate hotels in California, calls his approach “barefoot luxury”, focusing on the total well-being of his guests. Lauren Berger, who organises ultra-luxury travel experiences told me that her services are in high demand as people “seek not only absolute hospitality, but complete peace of mind”.

Another hidden factor is luxury as the ultimate treat. Consequently, highly personalised high-end beauty and well-being rituals are rebounding rapidly according to several industry sources.
Milk – a hyped, disruptive “affordable luxury” make-up brand that highlights “good ingredients, epic payoff” and celebrates optimism and inclusiveness – is a front runner among a cluster of inspirational, young and funky beauty brands that focus on a relaxed way of feeling good.

But good luck trying to buy high-end dumbbells or fitness equipment anywhere in the world. With home gyms booming, waiting times can be months now in the luxury segment. The more individualised and luxurious, the higher the demand.

And in fashion, brands like Hermès are showing an optimistic, relaxed and inspiring approach, generating dreams. “Our cave of wonders” is just one of the descriptions that Hermès uses on their website to describe their collection. It’s all about taking consumers from reality into a world where they can disconnect and just be.

Rolls-Royce has just revealed the first major redesign of the Spirit of Ecstasy – its iconic bonnet ornament. While luxury car enthusiasts started an immediate discussion whether the redesign is genius or an attack on history, Rolls-Royce got its brand featured everywhere, getting in front of potential luxury customers that so far may never have considered or driven what some people call “the pinnacle of luxury”.

All these examples underline that luxury truly is the ability to create extreme value. Brands that manage to excite their customers through inspiration, innovation, and aspiration, always with the customer at the centre, will be driving the rebound of luxury. And through the most influential brands, the luxury sector will lead the economic rebound at large. Isn’t a little excitement what we all need in these challenging times?

>>> Europe : Brokers Upgrades & Downgrades - 1st of September 2020 -V2(+)

>>> Up
* Davide Campari-Milano NV Raised to Overweight at JPMorgan
* GEA Group Raised to Buy at Bankhaus Metzler; PT 36 euros
* Hargreaves Lansdown Raised to Hold at Jefferies; PT 1,520 pence
* Helios Towers Raised to Buy at BofA; PT 192 pence (+)
* HELMA Eigenheimbau Raised to Buy at Bankhaus Metzler
* Ipsen PT Raised to 101 euros from 90 euros at Morgan Stanley
* Novartis Raised to Overweight at Morgan Stanley
* PetroNor E&P Raised to Buy at SpareBank; PT 1.20 kroner
* USU SOFTWARE Raised to Buy at Hauck & Aufhaeuser (+)
* Veolia Raised to Buy at BofA; PT 25 euros (+)
* Zalando Raised to Buy at Goldman; PT 87 euros

>>> Down
* Aroundtown Cut to Neutral at Goldman; PT 5 euros
* BCP Cut to Hold at Jefferies; PT 11 euro cents
* Deutsche Wohnen Cut to Sell at Goldman; PT 37.20 euros
* IAG Cut to Neutral at JPMorgan; PT 223.48 pence
* Inditex Cut to Neutral at Goldman; PT 26 euros
* Sabadell Cut to Underperform at Jefferies; PT 29 euro cents

>>> Initiation
* AJ Bell Rated New Underperform at Jefferies; PT 280 pence
* Allgeier Rated New Buy at Commerzbank; PT 76 euros
* Boliden Rated New Buy at SEB Equities; PT 294 kronor
* Brenntag Reinstated Buy at BofA; PT 66 euros (+)
* Evotec SE Rated New Buy at Citi; PT 29.50 euros
* Lok'nStore Group Rated New Add at Peel Hunt; PT 650 pence

>>> Call
* Jefferies Likes S. Europe Banks Prepared for Good and Bad Times
* Nestle’s Aimmune Purchase Shows Sales Growth Difficulty: RBC

>>> Stoxx 600 Pre-Market Indications

  • TUI (TUI1 TH) +2.5%
  • Glaxo (GS7 TH) +2.3%
  • Evonik (EVK TH) +2.3%
  • Freenet (FNTN TH) +1.8%
  • Zalando (ZAL TH) +1.6%
    • Zalando Raised to Buy at Goldman; PT 87 euros
  • Prosus (1TY TH) +1.5%
    • Prosus Spends to Expand Food-Delivery Revenue: Earnings Outlook
  • TeamViewer (TMV TH) +1.5%
    • Watch Work-From-Home Winners After Zoom Blows Past Estimates
  • AstraZeneca (ZEG TH) +1.3%
  • Boliden (BWJQ TH) +1.2%
    • Boliden Rated New Buy at SEB Equities; PT 294 kronor
  • GEA Group (G1A TH) +1.1%
    • GEA Group Raised to Buy at Bankhaus Metzler; PT 36 euros
  • Sanofi (SNW TH) -0.6%
    • Sanofi Ends Testing on Covid Treatment After Weak Results
  • Nemetschek (NEM TH) -0.7%
  • Siemens Gamesa (GTQ1 TH) -0.8%
  • Ryanair (RY4C TH) -2%
  • Deutsche Wohnen (DWNI TH) -2.3%
    • Deutsche Wohnen Cut to Sell at Goldman; PT 37.20 euros
  • IAG (INR TH) -6.8%
    • IAG Cut to Neutral at JPMorgan; PT 223.48 pence

>>> TradeGate Pre-Market Indications

DAX:
  • Bayer (BAYN TH) +1.1%
    • Bayer to Buy Vitamin Company Care/Of at $225 Million Valuation
  • Fresenius SE (FRE TH) +1%
    • Fresenius SE Conference Scheduled By Commerzbank for Sept. 1-3
  • BMW (BMW TH) +0.8%
    • Ford to Cut 1,000 North America Salaried Jobs Amid Overhaul
  • Deutsche Wohnen (DWNI TH) -2.6%
    • Deutsche Wohnen Cut to Sell at Goldman; PT 37.20 euros
MDAX:
  • Rocket Internet (RKET TH) +5.5%
    • Rocket Internet to Buy Shares at EU18.57 in Delisting Offer
  • Freenet (FNTN TH) +2.7%
    • Freenet Launches Share Buyback Program for Up to EU100m
  • Zalando (ZAL TH) +2.1%
    • Zalando Raised to Buy at Goldman; PT 87 euros
  • GEA Group (G1A TH) +1.1%
    • GEA Group Raised to Buy at Bankhaus Metzler; PT 36 euros
SDAX:
  • Draegerwerk (DRW3 TH) +1.1%
  • LPKF (LPK TH) +1%

WWD : L’Oréal Introduces Second Employee Share Ownership Plan

L’Oréal Introduces Second Employee Share Ownership Plan
Under the scheme, company employees will be able to buy 500,000 shares at a discounted rate.

PARIS — L’Oréal said it is launching a second employee share ownership plan, which will be introduced in 57 countries.

Under the plan, group employees will be able to buy 500,000 shares at a discounted rate. The subscription period will run from Sept. 17 to Oct. 2, and settlement is scheduled for Nov. 3.

The shares will trade on the Euronext stock exchange in Paris, but will have to be held for at least five years, barring exceptions.

“This year, after the success of the first plan in 2018, we want to once again involve our employees in the prosperity of our group,” said Jean-Paul Agon, chairman and chief executive officer of L’Oréal, in a statement released Monday.

“This second employee share ownership plan is a new opportunity to allow those who wish to do so support the development of the company and participate in its strategic project. This new plan reaffirms our ambition to unite our employees even more closely with L’Oréal’s future.”

The company’s first employee share ownership plan was launched in the summer of 2018.

>>> What to look at today - 1st of September 2020

The dollar extended losses at the start of a new month to trade at its lowest since May 2018. Asian stocks drifted after a retreat in most U.S. equities with the exception of technology shares.
The euro led the charge against the beleaguered greenback and approached the closely watched $1.20 level. China’s yuan touched the highest since 2019 as manufacturing data indicated that exports are underpinning a recovery.
Australian shares underperformed, led by a decline in financials, while South Korean equities advanced as the government prepares to boost its budget in 2021. Equities fluctuated elsewhere in Asia. S&P 500 futures edged up after the benchmark notched a fifth consecutive monthly increase in August. European contracts rose. Treasuries were little changed. Indian bonds climbed in the wake of Reserve Bank of India steps to boost demand for government notes.
US After Hours  ZM +21.5% zooms higher on earnings; KODK +35.8% up big as D.E. Shaw discloses 5.2% passive stake

Nikkei +0.02% Hang Seng +0.10% CSI +0.14% Shanghai +0.06% Shenzen +0.18%

Eur$ 1.1992 CNH 6.8189 CNY 6.8180 JPY 105.64 GBP 1.3418 CHF 0.9006 RUB 73.6230 WTI$ 43.05 +1.03%

S&P +0.16% NAsdaq +0.43% EuroStoxx +0.80% FTSE -0.32% Dax +0.75% SMI +0.28%

Macro :
- Germany Expects 2020 Contraction Won’t Be as Deep as Forecast

Keep an eye on :
- AA/ LN : Warburg Pincus in Talks to Join Forces for AA Takeover Bid: Sky
- AC FP : French June Hotel Stays Fall 73%; High-End Hotels Hit Hardest
- AMUN FP : Amundi Says Beware ‘Walking Dead’ Firms in High-Yield Credit
- AR4 GY : Aurelius CFO Schiefer Steps Down for Health Reasons
- AVV LN : Aveva’s $5 Billion Deal Is First of Many as Factories Go Digital
- AZN LN : AstraZeneca U.S. Vaccine Trial Starts After Delay, Hospital Says
- BAYN GY : Bayer to Buy Vitamin Company Care/Of at $225 Million Valuation
- BMPS IM : Italy Readies Sale of Monte Dei Paschi Di Siena Stake: Reuters
- BMW GY : BMW Cutting White-Collar Jobs in U.S. Business Amid Sales Slump
- ECONB BB : Econocom to Buy B2B Business of Belgian Apple Reseller Switch
- FNTN GY : Freenet Launches Share Buyback Program for Up To EU100m
- ITMR IM : At-Home Apnea Test Maker Itamar Gains After SLEEP Meeting
- EGL PL : Mota-Engil Signs $335m Contract for Road Project in Angola
- ENGI FP : Suez Board Says Veolia Offer Carries ‘Great Uncertainty’
- EUCAR FP : Hertz Is Said to Weigh Donlen Leasing Business Sale to Pay Debt
- MMB FP : Lagardère Board Rejects Extraordinary General Meeting Request
- MMB FP : Vivendi, Amber Seek Court Backing for Lagardere Holder Meeting
- OCDO LN : Ocado to Deliver Marks & Spencer Food Range Products From Sept.
- PHIA NA : Philips Seeks to Recover Some Costs for U.S. Order: F.A.Z.
- RNO FP : French Aug. New Car Registrations Drop 20%: CCFA
- ROG SW : Roche Gets FDA Approval for HIV-1/HIV-2 Test on Cobas Systems
- SAN FP : Sanofi Says Kevzara Didn’t Meet Main Goal in Covid-19 Study
- SZE FP : Suez Board Says Veolia Offer Carries ‘Great Uncertainty’
- TMV GY : Watch Work-From-Home Winners After Zoom Blows Past Estimates
- TIT IM : Telecom Italia Approves Letter of Intent With CDP on Grid
- TIT IM : Telecom Italia Approves Landmark Sale of Stake in Italy Network
- FP FP : Total, Macquarie to Develop Offshore Wind Power in South Korea
- TUI LN : TUI Flight to Wales Told to Quarantine After Virus Cases Found
- UBI FP : Ubisoft Removes Video Seen as Insensitive to Black Lives Matter
- VIE FP : Suez Board Says Veolia Offer Carries ‘Great Uncertainty’
- VRLA FP : Verallia Says CFO Fontaine to Leave for Another Company
- ZAG AV : Zumtobel First Quarter Profit EU3.1 Mln, -72% Y/y

>>> Europe : Brokers Upgrades & Downgrades - 1st of September 20

>>> Up
* Davide Campari-Milano NV Raised to Overweight at JPMorgan
* GEA Group Raised to Buy at Bankhaus Metzler; PT 36 euros
* Hargreaves Lansdown Raised to Hold at Jefferies; PT 1,520 pence
* HELMA Eigenheimbau Raised to Buy at Bankhaus Metzler
* Ipsen PT Raised to 101 euros from 90 euros at Morgan Stanley
* Novartis Raised to Overweight at Morgan Stanley
* PetroNor E&P Raised to Buy at SpareBank; PT 1.20 kroner
* Zalando Raised to Buy at Goldman; PT 87 euros

>>> Down
* Aroundtown Cut to Neutral at Goldman; PT 5 euros
* BCP Cut to Hold at Jefferies; PT 11 euro cents
* Deutsche Wohnen Cut to Sell at Goldman; PT 37.20 euros
* IAG Cut to Neutral at JPMorgan; PT 223.48 pence
* Inditex Cut to Neutral at Goldman; PT 26 euros
* Sabadell Cut to Underperform at Jefferies; PT 29 euro cents

>>> Initiation
* AJ Bell Rated New Underperform at Jefferies; PT 280 pence
* Allgeier Rated New Buy at Commerzbank; PT 76 euros
* Boliden Rated New Buy at SEB Equities; PT 294 kronor
* Evotec SE Rated New Buy at Citi; PT 29.50 euros
* Lok'nStore Group Rated New Add at Peel Hunt; PT 650 pence

>>> Call
* Jefferies Likes S. Europe Banks Prepared for Good and Bad Times

>>> US After Hours Summary: ZM +21.5% zooms higher on earnings; KO

After Hours Summary: ZM +21.5% zooms higher on earnings; KODK +35.8% up big as D.E. Shaw discloses 5.2% passive stake

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: ZM +21.5%, SITM +4.7%, COHU +1.5%, RXT +0.2%

Companies trading higher in after hours in reaction to news: KODK +35.8% (D.E. Shaw discloses 5.2% passive stake), TTOO +17.3% (receives FDA Emergency Use Authorization for T2SARS-CoV-2 Panel), WPRT +17.1% (awarded electronics supply contract from "tier one" automotive supplier), FLR +2.4% (highlights US Nuclear Regulatory Commission design certification), AZN +0.9% (confirms development plans for COVID-19 vaccine AZD1222), CCL +0.7% (Seabourn unit announces additional voyage cancellations), MDT +0.5% (FDA grants approval to MiniMed770G System in young pediatric patients), GSK +0.3% (announces first participant vaccinated in Phase 3 trial for Meningitis ABCWY), SVM +0.1% (reports 18% increase in silver resources at Ying property)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: SCSC -8.5%

Companies trading lower in after hours in reaction to news: ZSAN -16% (stock offering), PRPL -3% (stock offering), UBX -0.6% (new CFO), AFG -0.1% (new CFO)

Reuters : Scientists see downsides to top COVID-19 vaccines from Russia, China

Scientists see downsides to top COVID-19 vaccines from Russia, China - https://reut.rs/2EHem6Q

TORONTO/CHICAGO (Reuters) - High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.

CanSino Biologics’ vaccine, approved for military use in China, is a modified form of adenovirus type 5, or Ad5. The company is in talks to get emergency approval in several countries before completing large-scale trials, the Wall Street Journal reported last week.

A vaccine developed by Moscow’s Gamaleya Institute, approved in Russia earlier this month despite limited testing, is based on Ad5 and a second less common adenovirus.

“The Ad5 concerns me just because a lot of people have immunity,” said Anna Durbin, a vaccine researcher at Johns Hopkins University. “I’m not sure what their strategy is ... maybe it won’t have 70% efficacy. It might have 40% efficacy, and that’s better than nothing, until something else comes along.”

Vaccines are seen as essential to ending the pandemic that has claimed over 845,000 lives worldwide. Gamaleya has said its two-virus approach will address Ad5 immunity issues.

Both developers have years of experience and approved Ebola vaccines based on Ad5. Neither CanSino nor Gamaleya responded to requests for comment.

Researchers have experimented with Ad5-based vaccines against a variety of infections for decades, but none are widely used. They employ harmless viruses as “vectors” to ferry genes from the target virus – in this case the novel coronavirus - into human cells, prompting an immune response to fight the actual virus.

But many people already have antibodies against Ad5, which could cause the immune system to attack the vector instead of responding to the coronavirus, making these vaccines less effective.

Several researchers have chosen alternative adenoviruses or delivery mechanisms. Oxford University and AstraZeneca based their COVID-19 vaccine on a chimpanzee adenovirus, avoiding the Ad5 issue. Johnson & Johnson’s candidate uses Ad26, a comparatively rare strain.

Dr. Zhou Xing, from Canada’s McMaster University, worked with CanSino on its first Ad5-based vaccine, for tuberculosis, in 2011. His team is developing an inhaled Ad5 COVID-19 vaccine, theorizing it could circumvent pre-existing immunity issues.

“The Oxford vaccine candidate has quite an advantage” over the injected CanSino vaccine, he said.

Xing also worries that high doses of the Ad5 vector in the CanSino vaccine could induce fever, fueling vaccine skepticism.

“I think they will get good immunity in people that don’t have antibodies to the vaccine, but a lot of people do,” said Dr. Hildegund Ertl, director of the Wistar Institute Vaccine Center in Philadelphia.

In China and the United States, about 40% of people have high levels of antibodies from prior Ad5 exposure. In Africa, it could be has high as 80%, experts said.

HIV RISK
Some scientists also worry an Ad5-based vaccine could increase chances of contracting HIV.

In a 2004 trial of a Merck & Co Ad5-based HIV vaccine, people with pre-existing immunity became more, not less, susceptible to the virus that causes AIDS.

Researchers, including top U.S. infectious diseases expert Dr. Anthony Fauci, in a 2015 paper, said the side effect was likely unique to HIV vaccines. But they cautioned that HIV incidence should be monitored during and after trials of all Ad5-based vaccines in at-risk populations.

“I would be worried about the use of those vaccines in any country or any population that was at risk of HIV, and I put our country as one of them,” said Dr. Larry Corey, co-leader of the U.S. Coronavirus Vaccine Prevention Network, who was a lead researcher on the Merck trial.

Gamaleya’s vaccine will be administered in two doses: The first based on Ad26, similar to J&J’s candidate, and the second on Ad5.

Alexander Gintsburg, Gamaleya’s director, has said the two-vector approach addresses the immunity issue. Ertl said it might work well enough in individuals who have been exposed to one of the two adenoviruses.

Many experts expressed skepticism about the Russian vaccine after the government declared its intention to give it to high-risk groups in October without data from large pivotal trials.

“Demonstrating safety and efficacy of a vaccine is very important,” said Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J’s COVID-19 vaccine. Often, he noted, large-scale trials “do not give the result that is expected or required.”